Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston. They discuss a phase I study with recent results that point to a potentially significant advance in the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

What is The Hematologist?

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.